WhiteCrystalSteroidHormonePowderLevonorgestrelskype:tracy665emailtracyatycphardotcomCAS797-63-7ForIrregularMenstruationUSP34CASNO.:797-63-7Assay:99%MolecularFormula:C21H28O2MolecularWeight:312.45Appearance:WhiteoralmostwhitecrystallinepowderUsage:Progesteronedrug,usedforirregularmenstruation,functionaluterinebleedingDescription:Levonorgestrelisahormonewhichissimilartothehormoneprogesteronethatisproducedbythebody.Itisusedtopreventwomenfrombecomingpregnant.Itworksbyincreasingthethicknessofvaginalfluidwhichcanstopaspermfromreachinganegg.Italsochangestheliningoftheuteruswhichmakesitdifficultforaneggtodevelop.Levonorgestrelmayincreasethechancesofdevelopingbreastcancer.YouandyourprescriberwillneedtoweighupthebenefitsandrisksoftakingLevonorgestrelbeforeyoustarttotakeit.WomenwhotakeLevonorgestrelneedtoregularlyexaminetheirbreastsforanychangesorlumps.Theprimarymechani***ofactionoflevonorgestrelasaprogestogen-onlyemergencycontraceptivepillis,accordingtoFIGO,topreventfertilizationbyinhibitionofovulation.Applicati***:Levonorgestrelisusedinwomentopreventpregnancyafterbirthcontrolfailure(e.g.,brokencondom)orunprotectedsex.Itisaprogestinhormonethatpreventspregnancybypreventingthereleaseofanegg(ovulation)andchangingthewombandcervicalmucustomakeitmoredifficultforaneggtomeetsperm(fertilization)orattachtothewallofthewomb(implantation).Usingthismedicationwillnotstopanexistingpregnancyorprotectyouagainstsexuallytran***itteddiseases(e.g.,HIV,gonorrhea,chlamydia).Levonorgestrel(orl-norgestrelorD-norgestrel)(PlanB,NextChoice,Postinor,"themorningafterpill,"andothers)isasecondgenerationprogestin(syntheticprogestogen)usedasanactiveingredientinsomehormonalcontraceptives,includingcombinedoralcontraceptivepills,progestogenonlypills,emergencycontraceptivepills,intrauterinesystems,contraceptiveimplants,andhormonereplacementtherapy.ItisontheWorldHealthOrganization'sListofEssentialMedicines,alistofthemostimportantmedicationneededinabasichealthsystem.Usage&Dosing:1.Oralcontraception:Atlowdoses,levonorgestrelisusedinmonophasicandtriphasicformulati***ofcombinedoralcontraceptivepills,with***ailablemonophasicdosesrangingfrom100-250μg,andtriphasicdosesof50μg/75μg/125μg.Atverylowdailydoseof30μg,levonorgestrelisusedinsomeprogestogenonlypillformulati***.2.EmergencycontraceptionLevonorgestrelisusedinemergencycontraceptivepills(ECPs),bothinacombinedYuzperegimenwhichincludesestrogen,andasalevonorgestrel-onlymethod.Thelevonorgestrel-onlymethoduseslevonorgestrel1.5mg(asasingledoseorastwo0.75mgdoses12hoursapart)takenwithin3daysofunprotectedsex,withonestudyindicatingthatbeginningaslateas120hours(5days)afterintercoursecouldbeeffective.Theprimarymechani***ofactionoflevonorgestrelasaprogestogen-onlyemergencycontraceptivepillis,accordingtoFIGO,topreventfertilizationbyinhibitionofovulation.TheInternationalFederationofGynecologyandObstetrics(FIGO)hasissuedastatementthat:"reviewoftheevidencesuggeststhatLNG[levonorgestreol]ECPscannotpreventimplantationofafertilizedegg.LanguageonimplantationshouldnotbeincludedinLNGECPproductlabeling."InJune2012,aNewYorkTimeseditorialcalledontheFoodandDrugAdministration(FDA)toremovefromthelabeltheunsupportedsuggestionthatlevonorgestrelemergencycontraceptivepillsinhibitimplantation.InNovember2013,theEuropeanMedicinesAgency(EMA)approvedachangetothelabelforHRAPharma'sNorLevosayingitcannotpreventimplantationofafertilizedegg.InNovember2013,theEMAalsoapprovedachangetothelabelforHRAPharma'sNorLevosaying:"Inclinicaltrials,contraceptiveefficacywasreducedinwomenweighing75kg[165pounds]ormore,andlevonorgestrelwasnoteffectiveinwomenwhoweighedmorethan80kg[176pounds]."InNovember2013andJanuary2014,theFDAandtheEMAsaidtheywerereviewingwhetherincreasedweightandbodymassindex(BMI)reducetheefficacyofemergencycontraceptives.LevonorgestrelisalsousedinIntrauterinesystem,ContraceptiveimplantsandHormonereplacementtherapy.Sideeffects:Afterintakeoflevonorgestrel1.5mginclinicaltrials,verycommoneffects(reportedby10%ormore)included:dizziness,headache,nausea,abdominalpain,uterinepain,delayofmenses,he***ymenses,uterinebleeding,orfatigue;commoneffects(reportedby1%to10%)includeddiarrhea,vomiting,orpainfulmenses;theseeffectsusuallydisappearedwithin48hours.COA:ItemsSpecificationResultsDescriptionWhiteorpracticallywhitecrystallinepowderWhitecrystallinepowderSpecificRotation30¡ã~-35¡ã32¡ãMeltingRange232~239¡ãC,andmeltingrangeisnotmorethen4¡ãC234~238¡ãCidentificationItcomplieswiththetestforspecificopticalrotationandmeltingpointConformsInfraredabsorptionspectrophotometryshouldbec***istentwithlevonorgestrelCRSConformsLossondrying¡Ü0.5%0.20%Residueonignition¡Ü0.3%0.07%LimitofEthynylGroup7.81%~8.18%7.92%RelatedsubstancesSingleimpurity¡Ü0.5%singleimpurity<0.5%TotalImpurities¡Ü2.0%Totalimpurities<2.0%OrganicVolatileimpurtiesEthanol¡Ü5000ppm1200ppmAssayTheproductcomplieswithspecificationinUSP34ParticleSizeD(0.9)<10¦&Igr***e;mStorageConditionSealed,protectfromlight)